Personalized adjuvant chemotherapy for stage II–III non-small cell lung cancer

Personalized adjuvant chemotherapy for stage II–III non-small cell lung cancer

Surgery is the standard of care for non-small cell lung cancer (NSCLC). The overall survival rates especially in patients with locally advanced lung cancer are low. The resistance of cancer cells to chemotherapeutic drugs reduces the efficacy of treatment. Special attention is paid to the feasibilit...

Full description

Saved in:
Bibliographic Details
Main Authors: E. O. Rodionov, S. V. Miller, M. M. Tsyganov, L. D. Zhuikova, L. V. Pikalova, O. V. Pankova, V. M. Perelmuter, D. V. Podolko, A. A. Mokh, O. A. Ananina, D. S. Pismenny, V. A. Markovich, D. M. Loos, N. V. Litvyakov
Format: Article
Language:Russian
Published: Russian Academy of Sciences, Tomsk National Research Medical Center 2024-01-01
Series:Сибирский онкологический журнал
Subjects:
resunon-small cell lung cancer
chemosensitivity
monoresistance genes
combined treatment
personalized adjuvant chemotherapy
Online Access:https://www.siboncoj.ru/jour/article/view/2834
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.siboncoj.ru/jour/article/view/2834

Similar Items